CA2165824C - Utilisation du modafinil pour la fabrication d'un medicament ayant un effet sur les apnees du sommeil et les troubles ventilatoires d'origine centrale - Google Patents
Utilisation du modafinil pour la fabrication d'un medicament ayant un effet sur les apnees du sommeil et les troubles ventilatoires d'origine centrale Download PDFInfo
- Publication number
- CA2165824C CA2165824C CA002165824A CA2165824A CA2165824C CA 2165824 C CA2165824 C CA 2165824C CA 002165824 A CA002165824 A CA 002165824A CA 2165824 A CA2165824 A CA 2165824A CA 2165824 C CA2165824 C CA 2165824C
- Authority
- CA
- Canada
- Prior art keywords
- modafinil
- treatment
- sleep apnea
- sec
- central origin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 229960001165 modafinil Drugs 0.000 title claims abstract description 18
- 238000011282 treatment Methods 0.000 title claims abstract description 16
- 201000002859 sleep apnea Diseases 0.000 title claims description 8
- 238000009423 ventilation Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000003519 ventilatory effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 208000008784 apnea Diseases 0.000 description 22
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 2
- 206010021079 Hypopnoea Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 101100172879 Caenorhabditis elegans sec-5 gene Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- PKIDMDXXGGEQEM-UHFFFAOYSA-N n-benzhydrylsulfinylacetamide Chemical compound C=1C=CC=CC=1C(S(=O)NC(=O)C)C1=CC=CC=C1 PKIDMDXXGGEQEM-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 238000002496 oximetry Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrotherapy Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Control Of Throttle Valves Provided In The Intake System Or In The Exhaust System (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR93/07555 | 1993-06-22 | ||
| FR9307555A FR2706767B1 (cg-RX-API-DMAC7.html) | 1993-06-22 | 1993-06-22 | |
| PCT/FR1994/000711 WO1995000132A1 (fr) | 1993-06-22 | 1994-06-14 | Utilisation du modafinil pour le traitement des apnees du sommeil et troubles ventilatoires d'origine centrale |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2165824A1 CA2165824A1 (fr) | 1995-01-05 |
| CA2165824C true CA2165824C (fr) | 2005-08-02 |
Family
ID=9448411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002165824A Expired - Lifetime CA2165824C (fr) | 1993-06-22 | 1994-06-14 | Utilisation du modafinil pour la fabrication d'un medicament ayant un effet sur les apnees du sommeil et les troubles ventilatoires d'origine centrale |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5612379A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0705099B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP3703831B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR100315389B1 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE207351T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU684087B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2165824C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69428791T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0705099T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2165878T3 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2706767B1 (cg-RX-API-DMAC7.html) |
| HU (1) | HU216731B (cg-RX-API-DMAC7.html) |
| PT (1) | PT705099E (cg-RX-API-DMAC7.html) |
| WO (1) | WO1995000132A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618845A (en) | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
| DK1066036T3 (da) | 1998-02-27 | 2006-08-21 | Univ Illinois | Midler med serotoninrelateret aktivitet til behandling af sövnapnö |
| US20060241164A1 (en) * | 1998-02-27 | 2006-10-26 | The Board Of Trustees Of The University Of Illinoi | Pharmacological treatment for sleep apnea |
| US7160898B2 (en) * | 2001-12-14 | 2007-01-09 | Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
| US6492396B2 (en) | 2000-05-16 | 2002-12-10 | Cephalon, Inc. | Substituted thioacetamides |
| ATE417608T1 (de) * | 2000-10-11 | 2009-01-15 | Cephalon Inc | Arzneizusammensetzungen enthaltend modafinilverbindungen |
| DE60219005T2 (de) * | 2001-05-25 | 2007-12-13 | Cephalon, Inc. | Modafinil umfassende feste pharmazeutische Formulierungen |
| US20080058424A1 (en) * | 2002-05-23 | 2008-03-06 | Cephalon, Inc. | Novel pharmaceutical formulations of modafinil |
| US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
| US20040048931A1 (en) | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
| US6992219B2 (en) * | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
| US20040116532A1 (en) | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| IL153098A0 (en) * | 2002-11-26 | 2003-06-24 | Chemagis Ltd | Pharmaceutical compositions containing modafinil |
| US7528172B2 (en) * | 2003-01-21 | 2009-05-05 | The Cooper Health System, Inc. | Compositions and methods for improving recovery after general anesthesia |
| EP1610796B1 (en) * | 2003-03-17 | 2014-04-23 | Neurohealing Pharmaceuticals, Inc. | High potency dopaminergic treatment of neurological impairment associated with brain injury |
| US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
| AR045423A1 (es) * | 2003-05-13 | 2005-10-26 | Cephalon Inc | Combinaciones de analiticos y antidepresivos |
| US7368591B2 (en) | 2003-09-19 | 2008-05-06 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
| US7449481B2 (en) * | 2004-04-13 | 2008-11-11 | Cephalon, Inc. | Thio-substituted biaryl-methanesulfinyl derivatives |
| US7297817B2 (en) * | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
| EP1586560A1 (en) * | 2004-04-13 | 2005-10-19 | Cephalon, Inc. | Thio-substituted arylmethanesulfinyl derivatives |
| US7119214B2 (en) * | 2004-04-13 | 2006-10-10 | Cephalon France | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives |
| US7423176B2 (en) * | 2004-04-13 | 2008-09-09 | Cephalon, Inc. | Bicyclic aromatic sulfinyl derivatives |
| US7314875B2 (en) * | 2004-04-13 | 2008-01-01 | Cephalon, Inc. | Tricyclic aromatic and bis-phenyl sulfinyl derivatives |
| AU2005319367B2 (en) * | 2004-12-20 | 2012-05-24 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
| US20090123545A1 (en) * | 2005-07-21 | 2009-05-14 | Ron Eyal S | Rapid Onset and Short Term Modafinil Compositions and Methods of Use Thereof |
| CA2657409A1 (en) * | 2006-07-12 | 2008-01-17 | Elan Corporation, Plc | Nanoparticulate formulations of modafinil |
| JP5395663B2 (ja) * | 2006-08-14 | 2014-01-22 | ニューロヒーリング・ファーマシューティカルズ・インコーポレーテッド | モダフィニルによる早漏の治療 |
| US20080181966A1 (en) * | 2006-10-18 | 2008-07-31 | Cephalon, Inc. | Modafinil pharmaceutical compositions |
| CN101641090B (zh) * | 2006-12-19 | 2012-12-05 | 亚勒斯有限公司 | 莫达非尼在制备治疗多动腿综合征的药物中的应用 |
| MX2012007813A (es) * | 2010-01-07 | 2012-08-01 | Vivus Inc | Tratamiento del sindrome de apnea obstructiva del sueño con una combinacion de un hinibidor de anhidrasa carbonica y un agente activo adicional. |
| CN105658227B (zh) | 2013-08-30 | 2020-04-03 | 绿十字生命健康有限公司 | 含有人参皂苷成分得到增加的加工人参粉末或加工人参提取物的用于预防及治疗癌因性疲乏的组合物 |
| US9616068B2 (en) | 2014-10-27 | 2017-04-11 | Pohela LLC | Animal training using cognitive enhancement |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1584462A (en) * | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
| FR2663225B1 (fr) * | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
| FR2684875B1 (fr) * | 1991-12-13 | 1995-05-24 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique. |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
-
1993
- 1993-06-22 FR FR9307555A patent/FR2706767B1/fr not_active Expired - Fee Related
-
1994
- 1994-06-14 JP JP50249895A patent/JP3703831B2/ja not_active Expired - Lifetime
- 1994-06-14 EP EP94919708A patent/EP0705099B1/fr not_active Expired - Lifetime
- 1994-06-14 AU AU70760/94A patent/AU684087B2/en not_active Expired
- 1994-06-14 US US08/564,286 patent/US5612379A/en not_active Expired - Lifetime
- 1994-06-14 ES ES94919708T patent/ES2165878T3/es not_active Expired - Lifetime
- 1994-06-14 AT AT94919708T patent/ATE207351T1/de active
- 1994-06-14 DK DK94919708T patent/DK0705099T3/da active
- 1994-06-14 CA CA002165824A patent/CA2165824C/fr not_active Expired - Lifetime
- 1994-06-14 WO PCT/FR1994/000711 patent/WO1995000132A1/fr not_active Ceased
- 1994-06-14 PT PT94919708T patent/PT705099E/pt unknown
- 1994-06-14 HU HU9503702A patent/HU216731B/hu unknown
- 1994-06-14 DE DE69428791T patent/DE69428791T2/de not_active Expired - Lifetime
- 1994-06-14 KR KR1019950705833A patent/KR100315389B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HU9503702D0 (en) | 1996-02-28 |
| DK0705099T3 (da) | 2002-02-11 |
| HUT74674A (en) | 1997-01-28 |
| FR2706767B1 (cg-RX-API-DMAC7.html) | 1995-09-08 |
| DE69428791T2 (de) | 2002-07-04 |
| US5612379A (en) | 1997-03-18 |
| DE69428791D1 (de) | 2001-11-29 |
| ES2165878T3 (es) | 2002-04-01 |
| CA2165824A1 (fr) | 1995-01-05 |
| FR2706767A1 (cg-RX-API-DMAC7.html) | 1994-12-30 |
| KR960703009A (ko) | 1996-06-19 |
| JP3703831B2 (ja) | 2005-10-05 |
| EP0705099A1 (fr) | 1996-04-10 |
| EP0705099B1 (fr) | 2001-10-24 |
| ATE207351T1 (de) | 2001-11-15 |
| JPH09500374A (ja) | 1997-01-14 |
| AU7076094A (en) | 1995-01-17 |
| WO1995000132A1 (fr) | 1995-01-05 |
| PT705099E (pt) | 2002-03-28 |
| HU216731B (hu) | 1999-08-30 |
| KR100315389B1 (ko) | 2002-02-19 |
| AU684087B2 (en) | 1997-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2165824C (fr) | Utilisation du modafinil pour la fabrication d'un medicament ayant un effet sur les apnees du sommeil et les troubles ventilatoires d'origine centrale | |
| Whyte et al. | Role of protriptyline and acetazolamide in the sleep apnea/hypopnea syndrome | |
| Pekkarinen et al. | Sleep apnoea and daytime sleepiness in acromegaly: relationship to endocrinological factors | |
| Clark et al. | Sleep apnea: treatment with protriptyline | |
| Orr et al. | Myxedema and obstructive sleep apnea | |
| Davila et al. | Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in nonsmokers. | |
| MXPA05002827A (es) | Formulaciones farmaceuticas de modafinil. | |
| IT8249698A1 (it) | Preparato farmaceutico contenente un sale di deferossammina per il trattamento di malattia di alzheimer | |
| Guilleminault et al. | From apnea of infancy to obstructive sleep apnea syndrome in the young child | |
| EP0563336A1 (en) | Pharmaceutical composition containing gamma-hydroxybutyric acid or its lactone in the treatment of drug dependence and nutritional disorders | |
| CN1152677C (zh) | 用异戊酸衍生物类cns抑制剂治疗强直、惊厥 | |
| DE60111025T2 (de) | Verwendung von Topiramat zur Behandlung und Diagnostizierung von Atemstörungen während des Schlafens und Mittel zur Durchführung der Behandlung und Diagnose | |
| JP2501033B2 (ja) | Ｄ―フェンフルラミン含有うつ病用医薬組成物 | |
| AU2005212149B2 (en) | Method of treating and diagnosing sleep disordered breathing using zonisamide and means for carrying out the method | |
| Sadasivam et al. | Anti-oxidant treatment in obstructive sleep apnoea syndrome | |
| WO2007046347A1 (ja) | 筋萎縮性側索硬化症患者の運動神経保護用医薬 | |
| Knezevic et al. | Neuroleptic malignant syndrome | |
| JP2001514219A (ja) | Ｌ−トレオン酸第１鉄、その医療組成物及び人間の貧血疾患を改善及び治療するためのその使用 | |
| JP6864964B2 (ja) | 経口睡眠改善剤 | |
| Guilleminault et al. | Baclofen trial in six myotonic dystrophy patients | |
| JPWO2020176432A5 (cg-RX-API-DMAC7.html) | ||
| SG172784A1 (en) | Novel use of fibrates | |
| US20250235475A1 (en) | Method of using melatonin lotion with magnesium to improve sleep quality and quantity | |
| JPWO2004100989A1 (ja) | いびき又は睡眠時の呼吸障害の予防・治療剤 | |
| Hori et al. | Electroencephalographic findings in neuroacanthocytosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20140616 |